 |
 Video: What is a Stock Split?
|
|
|
| Evolus is a beauty company focused on delivering products in the self-pay aesthetic market. Co.'s commercial product is Jeuveau® (prabotulinumtoxinA-xvfs), a proprietary purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Co.'s primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. According to our Evolus stock split history records, Evolus has had 0 splits. | |
|
Evolus (EOLS) has 0 splits in our Evolus stock split history database.
Looking at the Evolus stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Evolus shares, starting with a $10,000 purchase of EOLS, presented on a split-history-adjusted basis factoring in the complete Evolus stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/09/2018 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$11.66 |
|
| End price/share: |
$11.43 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-1.97% |
|
| Average Annual Total Return: |
-0.32% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$9,802.90 |
|
| Years: |
6.21 |
|
|
|
|
|
